Segment Information
We operate as a single reportable segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Our commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the nature of our operations and the financial information regularly reviewed by the chief executive officer, in his capacity as the chief operating decision maker (CODM), for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.
Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success is significantly dependent on our ability to research and develop innovative medicines. The CODM uses consolidated net income to assess performance of our company, ensuring that we are investing in future research and development while efficiently delivering products to patients. The CODM allocates research and development resources based upon several factors, including the likelihood of technical success, unmet medical needs, and the viability of commercial success. A significant component of the CODM’s decision-making process is to ensure a balanced investment in our research and development portfolio to drive near-term success and sustain for the long-term.
The following table summarizes information for our single reportable segment, including significant segment expenses:
| | | | | | | | | | | | | | | | | |
| 2025 | | 2024 | | 2023 |
| Revenue | $ | 65,179 | | | $ | 45,043 | | | $ | 34,124 | |
Less: | | | | | |
| Cost of sales | 11,052 | | | 8,418 | | | 7,082 | |
Early-stage research and development(1) | 4,881 | | | 3,917 | | | 3,093 | |
Late-stage research and development(1) | 8,456 | | | 7,074 | | | 6,221 | |
| Marketing, selling, and administrative | 11,094 | | | 8,594 | | | 7,404 | |
| Acquired in-process research and development | 2,910 | | | 3,280 | | | 3,800 | |
Other segment items(2) | 6,146 | | | 3,170 | | | 1,285 | |
| Net income | $ | 20,640 | | | $ | 10,590 | | | $ | 5,240 | |
| | | | | |
Expenditures for long-lived assets(3) | $ | 8,672 | | | $ | 5,561 | | | $ | 3,830 | |
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.
(2) Other segment items primarily include income taxes and asset impairment, restructuring, and other special charges.
(3) Includes expenditures for property and equipment and computer software costs.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.